COLL · Collegium Pharmaceutical, Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $780.57M | $631.45M | $566.77M | $463.93M | $276.87M | $310.02M |
| Cost of Revenue | $317.31M | $254.10M | $240.60M | $254.44M | $126.25M | $130.18M |
| Gross Profit | $463.26M | $377.34M | $326.17M | $209.49M | $150.62M | $179.84M |
| R&D | - | $0 | $0 | $3.98M | $9.45M | $9.77M |
| SG&A | $284.80M | $210.36M | $159.21M | $172.19M | $118.96M | $113.83M |
| Total Operating Expenses | $283.62M | $207.45M | $159.21M | $176.17M | $132.99M | $123.60M |
| D&A | $4.18M | $3.86M | $3.50M | $2.68M | $1.74M | $870.0K |
| Operating Income | $179.64M | $169.90M | $166.96M | $33.32M | $17.63M | $56.23M |
| Interest Expense | $82.31M | $73.97M | $83.34M | $63.21M | $21.01M | $28.88M |
| Income Tax | $29.75M | $29.38M | $27.58M | ($3.85M) | ($74.89M) | $830.0K |
| Net Income | $62.87M | $69.19M | $48.16M | ($25.00M) | $71.52M | $26.75M |
| EPS - Basic | $1.98 | $2.14 | $1.43 | ($0.74) | $2.05 | $0.78 |
| EPS - Diluted | $1.73 | $1.86 | $1.29 | ($0.74) | $1.86 | $0.76 |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $231.25M | $70.56M | $238.95M | $173.69M | $186.43M | $174.12M |
| Accounts Receivable | $211.33M | $228.54M | $179.53M | $183.12M | $105.84M | $83.32M |
| Inventory | $40.91M | $35.56M | $32.33M | $46.50M | $17.39M | $15.61M |
| Accounts Payable | $10.66M | $3.93M | $8.69M | $3.49M | $4.19M | $10.02M |
| Current Assets | $691.41M | $482.26M | $537.60M | $419.99M | $315.54M | $277.89M |
| Total Assets | $1.66B | $1.66B | $1.14B | $1.17B | $692.08M | $643.84M |
| Current Liabilities | $440.03M | $509.51M | $457.92M | $433.73M | $279.57M | $239.45M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $1.36B | $1.43B | $947.88M | $979.29M | $489.15M | $457.81M |
| Stockholders' Equity | $301.68M | $228.84M | $195.43M | $194.84M | $202.93M | $186.03M |
| Retained Earnings | ($101.13M) | ($164.00M) | ($233.19M) | ($281.34M) | ($256.34M) | ($333.15M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $329.32M | $204.98M | $274.75M | $124.23M | $103.56M | $93.94M |
| Investing Cash Flow | ($63.53M) | ($287.76M) | ($70.81M) | ($573.69M) | ($1.94M) | ($373.77M) |
| Financing Cash Flow | ($110.25M) | ($60.60M) | ($140.18M) | $436.72M | ($89.30M) | $286.47M |
| CapEx | $1.74M | $1.65M | $461.0K | $1.62M | $1.94M | $5.55M |
| Free Cash Flow | $327.58M | $203.33M | $274.29M | $122.61M | $101.61M | $88.40M |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 59.3% | 59.8% | 57.5% | 45.2% | 54.4% | 58.0% |
| Operating margin | 23.0% | 26.9% | 29.5% | 7.2% | 6.4% | 18.1% |
| EBITDA margin | 23.5% | 27.5% | 30.1% | 7.8% | 7.0% | 18.4% |
| Net margin | 8.1% | 11.0% | 8.5% | -5.4% | 25.8% | 8.6% |
| Free cash flow margin | 42.0% | 32.2% | 48.4% | 26.4% | 36.7% | 28.5% |
| FCF / Net income | 5.21 | 2.94 | 5.70 | -4.90 | 1.42 | 3.30 |
| R&D / Revenue | - | 0.0% | 0.0% | 0.9% | 3.4% | 3.2% |
| SG&A / Revenue | 36.5% | 33.3% | 28.1% | 37.1% | 43.0% | 36.7% |
| Effective tax rate | 32.1% | 29.8% | 36.4% | - | - | 3.0% |
| Return on assets | 3.8% | 4.2% | 4.2% | -2.1% | 10.3% | 4.2% |
| Return on equity | 20.8% | 30.2% | 24.6% | -12.8% | 35.2% | 14.4% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 1.57 | 0.95 | 1.17 | 0.97 | 1.13 | 1.16 |
| Quick ratio | 1.48 | 0.88 | 1.10 | 0.86 | 1.07 | 1.10 |
| Cash ratio | 0.53 | 0.14 | 0.52 | 0.40 | 0.67 | 0.73 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | 2.2x | 2.3x | 2.0x | 0.5x | 0.8x | 1.9x |
| Equity multiplier | 5.49 | 7.27 | 5.85 | 6.03 | 3.41 | 3.46 |
| Liabilities / Assets | 0.82 | 0.86 | 0.83 | 0.83 | 0.71 | 0.71 |
| Efficiency | ||||||
| Asset turnover | 0.47 | 0.38 | 0.50 | 0.40 | 0.40 | 0.48 |
| Inventory turnover | 7.76 | 7.15 | 7.44 | 5.47 | 7.26 | 8.34 |
| Days sales outstanding | 99d | 132d | 116d | 144d | 140d | 98d |
| Days inventory outstanding | 47d | 51d | 49d | 67d | 50d | 44d |
| Days payable outstanding | 12d | 6d | 13d | 5d | 12d | 28d |
| Cash conversion cycle | 134d | 178d | 151d | 206d | 178d | 114d |
| Valuation | ||||||
| P / E | 26.8x | 15.4x | 23.9x | - | 10.0x | 26.4x |
| P / B | 6.1x | 5.1x | 6.6x | 4.0x | 3.8x | 3.8x |
| P / S | 2.4x | 1.8x | 2.3x | 1.7x | 2.8x | 2.3x |
| EV / EBITDA | 8.7x | 6.3x | 6.1x | 17.0x | 30.0x | 9.3x |
| Growth | ||||||
| Revenue growth (YoY) | 23.6% | 11.4% | 22.2% | 67.6% | -10.7% | 4.5% |
| Revenue CAGR (3y) | 18.9% | 31.6% | 22.3% | 16.1% | 444.9% | - |
| Revenue CAGR (5y) | 20.3% | 16.3% | 219.2% | - | - | - |
| Gross profit growth (YoY) | 22.8% | 15.7% | 55.7% | 39.1% | -16.2% | 74.5% |
| Operating income growth (YoY) | 5.7% | 1.8% | 401.1% | 89.0% | -68.7% | - |
| Net income growth (YoY) | -9.1% | 43.7% | - | - | 167.3% | - |
| EPS growth (YoY) | -7.0% | 44.2% | - | - | 144.7% | - |
| EPS CAGR (3y) | - | 0.0% | 19.3% | - | - | - |
| EPS CAGR (5y) | 17.9% | - | - | - | - | - |
| FCF growth (YoY) | 61.1% | -25.9% | 123.7% | 20.7% | 15.0% | 314.1% |
| FCF CAGR (5y) | 30.0% | 57.0% | 10.8% | - | - | - |
| Book value growth (YoY) | 31.8% | 17.1% | 0.3% | -4.0% | 9.1% | 112.8% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$780.57M totalSingle Reportable Segment$780.57M · 100.0%
Product / service
$780.57M totalBelbuca$221.65M · 28.4%
Xtampza ER$199.31M · 25.5%
Jornay Pm$148.86M · 19.1%
Nucynta IR$115.31M · 14.8%
Nucynta ER$80.98M · 10.4%
Symproic And Other$14.45M · 1.9%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
0.96
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
6/9
Neutral
- ✓Net income positive
- ✓Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✓No share dilution
- ✗Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing COLLEGIUM PHARMACEUTICAL against the 5 most active filers in the same SIC group.